Aldesleukin: profile and news

Other information

Indication
For treatment of adults with metastatic renal cell carcinoma

Pharmacology
Used to treat renal cell carcinoma, proleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.

Mechanism Of Action
Proleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.

Drug Category
Antineoplastic Agents

Brand Names/Synonyms
Interleukin-2 precursor;IL-2;T-cell growth factor;TCGF; Proleukin (Chiron Corp)

Dosage Forms
POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human interleukin 2 (modified)

Chemical Formula
C690H1115N177O202S6

Half Life
13 min-85 min

Drug Type
Approved Drug

# Accession No
BIOD00082

CAS Registry Number
85898-30-2